Hepatitis B Antiviral Agents

A compound of Formula II:

• or a pharmaceutically acceptable salt thereof;
• wherein
• ring A is a monocyclic or bicyclic aryl or a monocyclic or bicyclic heteroaryl ring;
• ring B is a monocyclic or bicyclic aryl or a monocyclic or bicyclic heteroaryl ring;
• R1 is SO2N(R6)R7 or C(═O)N(H)R6;
• R2 and R5 are independently selected at each occurrence from the group consisting of halo, —CN, —NO2, -(L)m-OR8, -(L)m-SR9, -(L)m-S(═O)R9, -(L)m-S(═O)2R9, -(L)m-NHS(═O)2R9, -(L)m-C(═O)R9, -(L)m-OC(═O)R9, -(L)mCO2R8, -(L)m-OCO2R8, -(L)m-CH(R8)2, -(L)m-N(R8)2, -(L)m-C(═O)N(R8)2, -(L)m-OC(═O)N(R8)2, -(L)m-NHC(═O)NH(R8), -(L)m-NHC(═O)R9, -(L)m-NHC(═O)OR9, -(L)m-C(OH)(R8)2, -(L)mC(NH2)(R8)2, —C1-C6 alkyl, —C1-C6 fluoroalkyl and —C1-C6 heteroalkyl;
• R3 is C or S(═O);
• R4 is H, C1-C6 alkyl, C1-C6 heteroalkyl, —C1-C3alkyl-(C3-C6 cycloalkyl) or -(L)m-aryl, and wherein the alkyl, heteroalkyl, cycloalkyl or aryl group is optionally substituted with 0-5 substituents selected from R2;
• R6 and R7 are independently selected from the group consisting of H, C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C6 heteroalkyl, C3-C10 cycloalkyl, C2-C10 heterocycloalkyl, aryl, heteroaryl, —C1-C4 alkyl-(C3-C10 cycloalkyl), —C1-C4 alkyl-(C2-C10 heterocycloalkyl), —C1-C4 alkyl-(aryl), or —C1-C4 alkyl(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl group is optionally substituted with 0-5 substituents selected from R2, or the R6 and R7 groups attached to the same N atom are taken together with the N atom to which they are attached to form an optionally substituted C2-C10 heterocycloalkyl ring, wherein the ring optionally comprises a moiety selected from O, C═O, S(O)m, NR4S(O)m, NR4(C═O) or N—R4, and wherein the cycloalkyl or heterocycloalkyl ring is optionally substituted with 0-5 substituents selected from R2;
• each R8 is independently, at each occurrence, H, C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C6 heteroalkyl, C3-C10 cycloalkyl, C2-C10 heterocycloalkyl, aryl, heteroaryl, —C1-C4 alkyl-(C3-C10 cycloalkyl), —C1-C4 alkyl-(C2-C10 heterocycloalkyl), —C1-C4 alkyl-(aryl), or —C1-C4 alkyl(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally substituted with 0-5 substituents selected from R2;
• or two R8 groups attached to the same N or C atom are taken together with the N or C atom to which they are attached to form an optionally substituted C2-C10 heterocycloalkyl or C3-C10 heterocycloalkyl, wherein the ring optionally comprises a moiety selected from 0, C═O, S(O)m, NR4S(O)m, NR4(C═O) or N—R4, and wherein the ring is optionally substituted with 0-5 substituents selected from R2;
• R9 is C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C6 heteroalkyl, C3-C10 cycloalkyl, a C2-C10 heterocycloalkyl, aryl, heteroaryl, —C1-C4 alkyl-(C3-C10 cycloalkyl), —C1-C4 alkyl-(C2-C10 heterocycloalkyl), —C1-C4 alkyl-(aryl), or —C1-C4 alkyl-(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring is optionally substituted with 0-5 substituents selected from R2;
• each occurrence of x and y is independently selected from the group consisting of 0, 1, 2, 3 and 4;
• L is independently, at each occurrence, a bivalent radical selected from —(C1-C3 alkylene)m-, —(C3-C7 cycloalkylene), —(C1-C3 alkylene)m-O—(C1-C3 alkylene)m-, or —(C1-C3 alkylene)m-NH—(C1-C3 alkylene)m-;
• and,
• each occurrence of m is independently 0, 1 or 2.